ProPhase Labs Inc
$ 0.52
-15.45%
26 Dec - close price
- Market Cap 2,177,700 USD
- Current Price $ 0.52
- High / Low $ 0.62 / 0.50
- Stock P/E N/A
- Book Value 1.65
- EPS -19.80
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.24 %
- ROE -2.20 %
- 52 Week High 9.35
- 52 Week Low 0.50
About
ProPhase Labs, Inc. is a forward-thinking health and wellness company headquartered in Garden City, New York, dedicated to the research, development, and commercialization of innovative consumer health products and over-the-counter dietary supplements. With a strong emphasis on quality and efficacy, ProPhase Labs is well-positioned within the dynamic wellness market, effectively catering to evolving consumer needs with its diverse range of health solutions. The company’s strategic focus on product efficacy and market expansion underscores its potential as an attractive investment opportunity for institutional investors aiming to capitalize on the burgeoning health sector.
Analyst Target Price
$13.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-13 | 2025-05-07 | 2025-03-13 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-15 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-28 |
| Reported EPS | -0.1646 | -0.11 | -0.1328 | -1.59 | -0.35 | -0.33 | -0.07 | -0.51 | -0.3 | -0.2 | 0.03 | -0.12 |
| Estimated EPS | -0.11 | -0.15 | -0.18 | -0.24 | 0.04 | -0.24 | -0.28 | -0.26 | -0.19 | -0.14 | -0.09 | 0.03 |
| Surprise | -0.0546 | 0.04 | 0.0472 | -1.35 | -0.39 | -0.09 | 0.21 | -0.25 | -0.11 | -0.06 | 0.12 | -0.15 |
| Surprise Percentage | -49.6364% | 26.6667% | 26.2222% | -562.5% | -975% | -37.5% | 75% | -96.1538% | -57.8947% | -42.8571% | 133.3333% | -500% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jun 2022 | Mar 2022 | Jan 1970 | Dec 2019 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | 2022-06-03 | 2022-03-10 | None | 2019-12-12 | None | None |
| Amount | $0.3 | $0.3 | $0.3 | $0.25 | $0.25 | $1.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRPH
2025-12-27 09:09:20
This article provides a comprehensive overview of ProPhase Labs (PRPH) stock, including its current price, historical data, and key financial metrics. It also features recent news, analyst ratings, and a comparison with competitors in the pharmaceuticals industry. The company is noted to be a diversified entity offering diagnostic services and consumer products.
2025-12-22 11:08:57
ProPhase Labs (PRPH) is undergoing significant changes, including a 1-for-10 reverse stock split that took effect on December 22, 2025, to regain Nasdaq compliance. Concurrently, the company has signed a non-binding Letter of Intent for a reverse merger with Advanced Biological Laboratories S.A. (ABL). This proposed merger would make ABL the majority owner, reshape ProPhase Labs' business, and potentially offer existing shareholders a special cash dividend and carve-outs related to Crown Medical Collections receivables, though the LOI is non-binding and subject to definitive agreements.
2025-12-20 10:09:50
ProPhase Labs announced it has signed a Letter of Intent for a reverse merger with Advanced Biological Laboratories, expecting the transaction to close in the first half of 2025. This news led to a significant jump in ProPhase Labs' stock price. The merger aims to leverage the combined strengths of both companies.
2025-12-20 10:09:50
ProPhase Labs Inc (NASDAQ:PRPH) stock surged 75.2% in premarket trading after announcing a non-binding letter of intent for a reverse merger with Advanced Biological Laboratories S.A. (ABL). ABL shareholders are expected to own approximately 76% of the combined entity, with ProPhase's legacy business valued at up to $30 million. The deal includes a potential special cash dividend for current ProPhase shareholders and the carving out of Crown Medical Collections receivables for existing shareholders.
2025-12-20 10:09:48
ProPhase Labs Inc (NASDAQ:PRPH) stock surged 75.2% in premarket trading after announcing a non-binding letter of intent for a reverse merger with Advanced Biological Laboratories S.A. (ABL). The deal anticipates ABL becoming the majority owner (approx. 76%) of the combined entity, valuing ProPhase’s legacy business at up to $30 million. Existing ProPhase shareholders may receive a special cash dividend of up to $10 million and would retain rights to approximately $50 million in Crown Medical Collections receivables.
2025-12-20 06:08:44
ProPhase Labs announced it has signed a Letter of Intent (LOI) for a reverse merger with Advanced Biological Laboratories, a European infectious disease diagnostics and therapeutics company. This news caused ProPhase Labs' shares to jump significantly, reflecting investor optimism about the potential acquisition. The merger aims to expand ProPhase Labs' presence in the diagnostics sector.
